Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT05696626
Title	Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation (ELAINEIII)
Acronym	ELAINEIII
Recruitment	Recruiting
Gender	both
Phase	Phase III
Variant Requirements	Yes
Sponsors	Sermonix Pharmaceuticals Inc.
Indications	estrogen-receptor positive breast cancer
Therapies	Abemaciclib + Fulvestrant Abemaciclib + Lasofoxifene
Age Groups:	senior \| adult
Covered Countries	USA \| TUR \| ROU \| POL \| ITA \| ISR \| GBR \| FRA \| ESP \| DEU \| CZE \| CAN \| BEL \| AUS